• news.cision.com/
  • Alligator Bioscience/
  • Alligator Bioscience Announces Approval of Collaboration Agreement with Johnson & Johnson Innovation by the US Federal Trade Commission
English

Alligator Bioscience Announces Approval of Collaboration Agreement with Johnson & Johnson Innovation by the US Federal Trade Commission

Report this content

Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, today announced that its agreement with Janssen Biotech, Inc. (Janssen), granting an exclusive worldwide license to Alligator’s clinical candidate ADC-1013 has been approved by the Federal Trade Commission under the Hart-Scott-Rodino act.

As a result of this approval Alligator Bioscience will receive an up-front payment and in a simultaneous transaction Johnson & Johnson Innovation - JJDC, Inc. will subscribe for new shares of Alligator common stock.

For further information please contact:

Claes Eriksson, CEO

Tel: +46 46 286 42 80

cle@alligatorbioscience.com

Subscribe